{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravitreal+injection+of+Aflibercept&page=2", "query": { "intervention": "Intravitreal injection of Aflibercept", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 160, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravitreal+injection+of+Aflibercept&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravitreal+injection+of+Aflibercept&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T17:44:26.378Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05769153", "title": "Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular Age-related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "AR-14034 SR implant lower dose", "type": "DRUG" }, { "name": "AR-14034 SR implant higher dose", "type": "DRUG" }, { "name": "AR-14034 SR implant", "type": "DRUG" }, { "name": "Aflibercept Injection", "type": "DRUG" }, { "name": "Sham procedure", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 139, "start_date": "2023-12-06", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 42, "location_summary": "Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05769153" }, { "nct_id": "NCT02559180", "title": "Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Retinopathy", "Macular Edema" ], "interventions": [ { "name": "aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rishi Singh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-10", "completion_date": "2020-12", "has_results": true, "last_update_posted_date": "2023-03-30", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02559180" }, { "nct_id": "NCT01578720", "title": "Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Choroidal Neovascularization", "Presumed Ocular Histoplasmosis" ], "interventions": [ { "name": "EYLEA (Aflibercept) intravitreal injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Retina Research Institute, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 5, "start_date": "2012-06", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 3, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01578720" }, { "nct_id": "NCT01942213", "title": "Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neovascular Age Related Macular Degeneration" ], "interventions": [], "intervention_types": [], "sponsor": "Prism Vision Group", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "65 Years to 90 Years" }, "enrollment_count": 136, "start_date": "2013-12", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-06-01", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 1, "location_summary": "Edison, New Jersey", "locations": [ { "city": "Edison", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01942213" }, { "nct_id": "NCT02713204", "title": "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "REGN910-3", "type": "DRUG" }, { "name": "Intravitreal Aflibercept Injection (IAI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 365, "start_date": "2016-03-31", "completion_date": "2017-10-03", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 87, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02713204" }, { "nct_id": "NCT03823300", "title": "A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Wet Macular Degeneration" ], "interventions": [ { "name": "Faricimab", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 658, "start_date": "2019-03-11", "completion_date": "2022-01-07", "has_results": true, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Mountain View", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03823300" }, { "nct_id": "NCT04603937", "title": "A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "KSI-301", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Sham Procedure", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kodiak Sciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 459, "start_date": "2020-09-30", "completion_date": "2023-08-31", "has_results": true, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04603937" }, { "nct_id": "NCT00789477", "title": "DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Laser Photocoagulation", "type": "PROCEDURE" }, { "name": "Intravitreal Aflibercept Injection", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 221, "start_date": "2008-12", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-09-09", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 42, "location_summary": "Artesia, California • Beverly Hills, California • Mountain View, California + 38 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00789477" }, { "nct_id": "NCT00509795", "title": "Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "ranibizumab", "type": "BIOLOGICAL" }, { "name": "aflibercept injection (VEGF Trap-Eye, BAY86-5321)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1217, "start_date": "2007-08", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-12-28", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509795" }, { "nct_id": "NCT02418754", "title": "Study of Intravitreal REGN2176-3 in Participants With Neovascular (\"Wet\") Age-Related Macular Degeneration (AMD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration" ], "interventions": [ { "name": "REGN2176-3", "type": "DRUG" }, { "name": "Intravitreal Aflibercept Injection (IAI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 505, "start_date": "2015-05-05", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2020-10-26", "last_synced_at": "2026-09-30T17:44:26.378Z", "location_count": 75, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02418754" } ] }